0.36
-0.0039(-1.07%)
Currency In USD
| Previous Close | 0.36 |
| Open | 0.37 |
| Day High | 0.37 |
| Day Low | 0.35 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.32 |
| Volume | 1.74M |
| Average Volume | 3.99M |
| Market Cap | 23.66M |
| PE | -0.97 |
| EPS | -0.37 |
| Moving Average 50 Days | 1.75 |
| Moving Average 200 Days | 1.25 |
| Change | -0 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $22.95 as of October 01, 2025 at a share price of $0.359. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $126.04 as of October 01, 2025 at a share price of $0.359.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
GlobeNewswire Inc.
Sep 29, 2025 11:05 AM GMT
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced mel
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
GlobeNewswire Inc.
Sep 23, 2025 12:05 PM GMT
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final data from Phase 2 basket trial
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with